Navigation Links
Torchmark Prices Senior Notes Offering
Date:6/25/2009

MCKINNEY, Texas, June 25 /PRNewswire-FirstCall/ -- Torchmark Corporation (NYSE: TMK) announced today that it has priced an offering of $300 million in aggregate principal amount of 9.25% Senior Notes that will mature in 2019. Torchmark expects the offering to close on June 30, 2009, subject to the satisfaction of customary closing conditions. The net proceeds of the offering will be used for the repayment of the $99.45 million in aggregate principal amount of Torchmark's 8.25% Senior Debentures that mature on August 15, 2009, and general corporate purposes.

Wachovia Capital Markets, LLC and SunTrust Robinson Humphrey, Inc. are acting as joint book-running managers for the offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the notes or any other securities, nor will there be any sale of the notes or any other securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The notes will be sold pursuant to Torchmark's effective shelf registration statement on file with the Securities and Exchange Commission.

The offering of the notes is being made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from:

    Wachovia Capital Markets, LLC
    c/o Wachovia Customer Information Center
    1525 West W.T. Harris Boulevard
    Charlotte, North Carolina 28262-0675
    Attention: Syndicate Operations
    1-800-326-5897

    SunTrust Robinson Humphrey, Inc.
    303 Peachtree Street, 24th Floor
    Mail Code: GA-ATLANTA-3947
    Atlanta, GA  30308
    Attention: Investment Grade Debt Capital Markets
    1-800-685-4786

Alternatively, the prospectus supplement and accompanying prospectus may be obtained by visiting the SEC's Web site at '/>"/>

SOURCE Torchmark Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Torchmark Corporation Announces Change in Domicile State of Insurance Subsidiaries to Nebraska
2. Torchmark Corporation Announces Fourth Quarter 2007 Earnings Release and Conference Call
3. Torchmark Corporation to Present at Merrill Lynch Insurance Investors Conference
4. Torchmark Corporation Reports First Quarter 2008 Results
5. Torchmark Corporation Declares Dividend
6. Torchmark Corporation Declares Dividend
7. Torchmark Corporation Announces Fourth Quarter 2008 Earnings Release and Conference Call
8. Torchmark Corporation to Present at Merrill Lynch Insurance Investors Conference
9. Torchmark Corporation Reports First Quarter 2009 Results
10. Lincare Holdings Inc. Prices $500 Million Convertible Senior Debentures Offering
11. American Association for Homecare Disputes Validity of Internet Power Wheelchair Prices as Basis for Reimbursement of Services in Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 2Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 3Health News:U.S. Cancer Cases, Deaths Continue to Drop 2Health News:U.S. Cancer Cases, Deaths Continue to Drop 3Health News:U.S. Cancer Cases, Deaths Continue to Drop 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 5Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 3Health News:Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients 2
Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3HemCon Medical Technologies Inc signs exclusive global agreement with Zimmer Dental Inc to distribute oral surgery dressings 57154 1HemCon Medical Technologies Inc signs exclusive global agreement with Zimmer Dental Inc to distribute oral surgery dressings 57154 2Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 1Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 2Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 3Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 4Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 1Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 2Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 3Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 4